Novelion

NVLN-T

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about NVLN-T

Signal
Opinion
Expert
WEAK BUY
WEAK BUY
August 26, 2004
Would buy the stocks. They would recommand people to look at this stock. However, this stock has been going up and down.
Show full opinionHide full opinion
Novelion (NVLN-T)
August 26, 2004
Would buy the stocks. They would recommand people to look at this stock. However, this stock has been going up and down.
BUY WEAKNESS
BUY WEAKNESS
August 23, 2004
At an interesting entry point. A competitor of theirs is in front of the FDA for approval of a competing drug for Visudine. This may create some weakness, but not a problem as there's plenty of room for both players.
Show full opinionHide full opinion
Novelion (NVLN-T)
August 23, 2004
At an interesting entry point. A competitor of theirs is in front of the FDA for approval of a competing drug for Visudine. This may create some weakness, but not a problem as there's plenty of room for both players.
HOLD
HOLD
August 17, 2004
The jury is out on this stock. Made a major acquisition and the market hasn't liked it very much. Would want to wait for one or two quarters before buying.
Show full opinionHide full opinion
Novelion (NVLN-T)
August 17, 2004
The jury is out on this stock. Made a major acquisition and the market hasn't liked it very much. Would want to wait for one or two quarters before buying.
HOLD
HOLD
August 3, 2004
The numbers have been a little slow on this company. There's always great expectations for biotech companies. Sales are coming in at a steady pace.
Show full opinionHide full opinion
Novelion (NVLN-T)
August 3, 2004
The numbers have been a little slow on this company. There's always great expectations for biotech companies. Sales are coming in at a steady pace.
DON'T BUY
DON'T BUY
July 30, 2004
The biotech area in Canada is a tough area to be in. A one trick pony. Has a fantastic drug for macular degenerative eye disorder. Some competition is coming out for them, possibly in the next few weeks.
Show full opinionHide full opinion
Novelion (NVLN-T)
July 30, 2004
The biotech area in Canada is a tough area to be in. A one trick pony. Has a fantastic drug for macular degenerative eye disorder. Some competition is coming out for them, possibly in the next few weeks.
BUY
BUY
July 22, 2004
Has dropped after the acquisition. Real cheap now.
Show full opinionHide full opinion
Novelion (NVLN-T)
July 22, 2004
Has dropped after the acquisition. Real cheap now.
DON'T BUY
DON'T BUY
July 14, 2004
Stock just broke below its 200 day moving average. That's a negative sign.
Show full opinionHide full opinion
Novelion (NVLN-T)
July 14, 2004
Stock just broke below its 200 day moving average. That's a negative sign.
DON'T BUY
DON'T BUY
July 7, 2004
Atrix was a big acquisition for a company this size. They want to broaden their product line and this acquisition will give them more opportunity, but not sure if they can handle the size of this.
Show full opinionHide full opinion
Novelion (NVLN-T)
July 7, 2004
Atrix was a big acquisition for a company this size. They want to broaden their product line and this acquisition will give them more opportunity, but not sure if they can handle the size of this.
DON'T BUY
DON'T BUY
June 30, 2004
Just did an acquisition. At this level, the stock is fairly valued. Has moved from being a biotech play to a specialty pharma.
Show full opinionHide full opinion
Novelion (NVLN-T)
June 30, 2004
Just did an acquisition. At this level, the stock is fairly valued. Has moved from being a biotech play to a specialty pharma.
HOLD
HOLD
June 17, 2004
Acquiring Atrix which is expensive, but transforms them into a multi-product company. Probably won't know if it works until 2006.
Show full opinionHide full opinion
Novelion (NVLN-T)
June 17, 2004
Acquiring Atrix which is expensive, but transforms them into a multi-product company. Probably won't know if it works until 2006.
HOLD
HOLD
June 14, 2004
Market didn't like news. Wait.
Show full opinionHide full opinion
Novelion (NVLN-T)
June 14, 2004
Market didn't like news. Wait.
DON'T BUY
DON'T BUY
May 28, 2004
Good company. Well-run. Can't see a lot of upside in terms of news flow.
Show full opinionHide full opinion
Novelion (NVLN-T)
May 28, 2004
Good company. Well-run. Can't see a lot of upside in terms of news flow.
HOLD
HOLD
May 11, 2004
Very pleased with its performance. Has been very successful with its main product Visodine. Probably will be range bound for a while. Doesn't have a strong pipeline. Has a lot of cash flow so will be able to make acquisitions.
Show full opinionHide full opinion
Novelion (NVLN-T)
May 11, 2004
Very pleased with its performance. Has been very successful with its main product Visodine. Probably will be range bound for a while. Doesn't have a strong pipeline. Has a lot of cash flow so will be able to make acquisitions.
DON'T BUY
DON'T BUY
April 20, 2004
Has had a big run and expects it to pause here for a little while. Have a lot of cash. Fully valued.
Show full opinionHide full opinion
Novelion (NVLN-T)
April 20, 2004
Has had a big run and expects it to pause here for a little while. Have a lot of cash. Fully valued.
DON'T BUY
DON'T BUY
April 13, 2004
Getting more and more approvals from HMOs and insurance companies. Probably at a peak right now. Could retreat 10/15%.
Show full opinionHide full opinion
Novelion (NVLN-T)
April 13, 2004
Getting more and more approvals from HMOs and insurance companies. Probably at a peak right now. Could retreat 10/15%.
Showing 31 to 45 of 190 entries